About the Authors

Mingxiang Li

Roles Investigation

Current address: Sutro Biopharma Inc., South San Francisco, CA, United States of America

Affiliation XOMA Corp., Berkeley, CA, United States of America

Dennis Lee

Roles Formal analysis, Investigation

Current address: Samsung BioLogics, Yeonsu-gu, Incheon, Republic of Korea

Affiliation XOMA Corp., Berkeley, CA, United States of America

Chidi R. Obi

Roles Investigation

Current address: Portola Pharmaceuticals, Inc., South San Francisco, CA, United States of America

Affiliation XOMA Corp., Berkeley, CA, United States of America

Joel K. Freeberg

Roles Conceptualization, Formal analysis, Methodology, Project administration, Supervision, Writing – original draft

Current address: Portola Pharmaceuticals, Inc., South San Francisco, CA, United States of America

Affiliation XOMA Corp., Berkeley, CA, United States of America

Shauna Farr-Jones

Roles Funding acquisition, Writing – original draft, Writing – review & editing

Affiliation Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America

Milan T. Tomic

Roles Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Writing – review & editing

milan.tomic@ologybio.com

Current address: Ology Bioservices, Inc., Berkeley, CA, United States of America

Affiliation XOMA Corp., Berkeley, CA, United States of America

Competing Interests

ML is the inventor of a patent covering the formation that is used in this study, the patent is assigned to XOMA Technology ltd. ML is currently an employee of SutroBioPharma Inc. JF and CO are currently employees of Portola Pharmaceuticals DL is currently an employee of Samsung Biologics. MTT is currently an employee of Ology Bioservices Inc, the company that is developing the subject antibodies. MTT, DL, ML CO and JF were previously employees of XOMA Corp, assignee of the patents covering the antibody co-formation. This does not alter our adherence of PLOS ONE policies on sharing data and Materials We have not disclosed the sequences of the antibodies because antibodies that are the subject of this publication are those that comprise therapeutics to be use for biodefense purposes and stockpiling by the US Government, As such, disclosure of the antibody sequence and epitopes would render these antibodies amenable to reverse engineering and circumvent their biodefense purpose.